Alpha adrenergic blocking agents: anti-nociceptive activity and enhancement of morphine-induced analgesia.
D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000698:Analgesia; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000201:enzymology / Q000378:metabolism; D002250:Carbon Radioisotopes; D004299:Dopamine beta-Hydroxylase / Q000037:antagonists & inhibitors; D004357:Drug Synergism; D006358:Hot Temperature; D008297:Male; D009020:Morphine / Q000378:metabolism / Q000494:pharmacology*; D009638:Norepinephrine / Q000037:antagonists & inhibitors; D010424:Pentobarbital / Q000494:pharmacology; D010643:Phenoxybenzamine / Q000378:metabolism / Q000494:pharmacology; D010646:Phentolamine / Q000494:pharmacology; D011217:Practolol / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D013997:Time Factors
D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; D002250:Carbon Radioisotopes; D010643:Phenoxybenzamine; D009020:Morphine; D011433:Propranolol; D004299:Dopamine beta-Hydroxylase; D010424:Pentobarbital; D011217:Practolol; D009638:Norepinephrine; D010646:Phentolamine